Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway

The article is broadly constructive on Eli Lilly and Johnson & Johnson, highlighting Lilly's Mounjaro and Zepbound growth, the launch of oral weight-loss drug Foundayo, and positive phase 3 retatrutide data. J&J posted 11% sales growth in innovative medicines, 7.7% growth in medtech, and nearly 10% total sales growth to more than $24 billion, with management targeting $100 billion in annual revenue. The macro view is cautious, warning that elevated S&P 500 valuations and persistent inflation could end the Trump-era bull market, but the piece argues these two healthcare names should remain resilient.

Analysis

The key market implication is not that defensive healthcare is suddenly “cheap,” but that the crowded late-cycle growth trade is starting to diversify into duration-neutral compounders. JNJ is the cleaner beneficiary versus KVUE because the market is likely to reward operating leverage in higher-margin segments while ignoring the lower-quality cash flows that still sit in consumer health. That creates a relative-value setup: capital rotating out of extended AI/mega-cap winners can still stay in equities, but it will likely compress the dispersion between secular growers and defensive quality, favoring names with visible mid-single-digit organic growth and shareholder returns.

The second-order effect is on portfolio construction, not just stock selection. If inflation stays sticky and rate cuts get pushed out, long-duration multiple expansion gets harder, which makes earnings resilience more valuable than narrative momentum. In that regime, JNJ can outperform not because it is exciting, but because it is one of the few large caps with enough scale, pricing power, and low cyclicality to absorb a slower macro backdrop while still compounding.

The market may be underestimating how much of this is a positioning unwind rather than a fundamental rerating. If investors start trimming high-beta winners, healthcare can receive a mechanical bid from de-risking flows, particularly from equity L/S and momentum funds rotating into lower-volatility names. The main risk to the thesis is a fast disinflation/risk-on rebound, which would re-ignite growth leadership and reduce the relative appeal of defensive pharma over the next 1-3 months.

The contrarian angle is that the best trade may not be owning the most obvious defensive stock, but avoiding the weakest adjacent asset: KVUE has less obvious earnings torque and less narrative support, so it can lag even in a defensive rotation. In other words, the article is directionally right on healthcare resilience, but the opportunity is probably in relative value and positioning rather than an outright chase of the whole basket.

Key Decisions for Investors

• Long JNJ / short KVUE as a 3-6 month relative-value pair: JNJ offers better earnings visibility and capital return support, while KVUE is more vulnerable to multiple compression if consumers stay pressured.
• Add JNJ on any 2-3% pullback over the next 2-4 weeks; target 8-12% upside over 6-9 months with lower drawdown than the broad market if inflation remains sticky.
• Sell out-of-the-money calls on JNJ against a core long for the next 1-2 quarters to monetize implied volatility if the stock is being bid as a defensive refuge.
• For macro hedging, pair a modest long JNJ with a partial short in a stretched growth basket over the next month to capture a potential factor rotation if rate-cut expectations continue to fade.
• Avoid initiating new momentum longs in the broad market until the next CPI/energy tape confirms disinflation; if risk-on reaccelerates, rotate back quickly because the defensive bid may fade within days.